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This study investigated whether partial hepatectomy 
enhances the growth of experimental liver metastases of 
colonic carcinoma in rats and whether treatment with 
recombinant human tumour necrosis factor (TNF)a can 
reduce this increased growth. Resection of 35 or 70 per cent 
of the liver was performed in inbred WAG rats, with sham- 
operated controls (five to eight animals per group). 
Immediately after surgery 5 x lo5 CC531 colonic tumour 
cells were injected into the portal vein. After 28 days the 
animals were killed and the number of liver metastases 
counted. A 35 per cent hepatectomy induced a significant 
increase in the median number of liver metastases (28 
versus 3 in controls), whereas a 70 per cent resection 
provoked excessive growth, consistently leading to more 
than 100 liver metastases and a significantly increased wet 
liver weight in all animals. TNF-a was given intravenously 
to rats following 70 per cent hepatectomy or sham 
operation in a dose of 160 pg/kg three times per week. This 
had only a marginal effect on tumour development in 
sham-operated rats but was very effective following partial 
hepatectomy (median 45 liver metastases). These 
observations c o n f i i  previous findings that surgical 
metastasectomy may act as a 'double-edged sword' by 
provoking outgrowth of dormant tumour cells and suggest 
that adjuvant treatment with TNF-a may be of benefit in 
patients undergoing resection of metastases. 
Surgical excision by partial hepatectomy is the only available 
method for prolonging the survival of patients with hepatic 
metastases from colorectal carcinoma. The 5-year survival 
rate of patients eligible for surgical resection (i.e. those with a 
solitary metastasis or a small tumour burden confined to the 
liver) is 25-40 per These results compare favourably 
with the natural outcome for this selected group of patients, 
who have a 5-year survival rate of less than 1 per cent'z4. 
However, despite the curative potential of hepatic resection, 
recurrence has been reported in 65-80 per cent of 
 patient^^-^, the majority being diagnosed within the first year 
after ~ p e r a t i o n ~ , ~ .  This suggests that the period immediately 
after resection may be of crucial importance for prognosis. 
It is obvious that the favourable survival rates achieved by 
surgery validate a continued policy of resection of metastatic 
liver disease. On the other hand, the high number of early 
recurrences suggests that resection might provoke enhanced 
tumour growth of occult metastases. Experimental research 
may provide clues for a modified surgical strategy or 
appropriately timed adjuvant therapy. 
Several groups have found experimental evidence for 
stimulation of tumour growth by partial hepatectomy in 
various animal models; both intrahepatic lesions and 
subcutaneously transplanted turnours were found to grow 
more quickly after this operations-y. 
There are various explanations for this phenomenon. 
Growth factors produced by the regenerating liver, such as 
hepatocyte growth factor, transforming growth factor B and 
epidermal growth factor, have been implicated as tumour 
growth-promoting agentsI0-l2. Other possible mechanisms 
include the detrimental effect of surgical manipulation 13, the 
generalized immunosuppression provoked by partial 
re~ect ion '~ and impaired Kupffer cell function". The aim of 
the present study was to investigate whether evidence could 
~ ~~ ~ 
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be found for enhanced growth of fresh liver metastases after 
partial resection in a rat model of colonic adenocarcinoma. 
Furthermore, it was investigated whether the putative growth 
stimulation could be inhibited or reversed by adjuvant treat- 
ment with tumour necrosis factor (TNF)a, an agent with 
proven efficacy against the colonic tumour under investiga- 
tion I h .  
Materials and methods 
Animals and tumour 
Male inbred WAG rats, 10-14 weeks old, weighing 250-275 g, and 
bred under specific pathogen-free conditions, were used. The rats 
were given standard rat food and water ad libitum. The 
experimental protocol adhered to rules laid down by the Dutch 
Animal Experimentation Act and was approved by the Committee 
on Animal Research of Erasmus University. 
Tumour CC531 is a moderately differentiated, weakly 
immunogenic colonic adenocarcinoma induced in a WAG rat by 
1 ,2-dimethy1hydrazinet7. The tumour is maintained in tissue culture 
as a monolayer in RPMI 1640 medium (Gibco, Paisley, UK), 
supplemented with 5 per cent fetal calf serum. A total of 5 X lo5  
cultured tumour cells were injected into the portal vein. The cells 
were harvested from stationary cultures by gentle trypsinization, 
providing cell suspensions with a viability greater than 95 per cent. 
Tumour CC531 is relatively insensitive to chemotherapy, but 
sensitive to the effects of biological response modifiers such as the 
interferon inducer bropirimine, interferon y and TNF-a". 
Experimental procedure 
Under ether anaesthesia the abdomen was opened through a 
midline incision. The left lateral and median liver lobes, represent- 
ing 70 per cent of the liver volume, were freed of fibrous attach- 
ments and exteriorized. The circulation in these lobes was 
temporarily interrupted by ligation of the hilar vessels. CC53 1 
tumour cells in 0.2 ml RPMI 1640 were injected into the portal vein 
through a 0.4 x 12-mm needle. Over 2 min the cells were directed 
through the remaining 30 per cent of the liver that was not ligated. 
The rats were then randomized into a partial hepatectomy group 
and a non-hepatectomy (sham) group. In the 70 per cent 
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hepatectomy group the temporary ligation was replaced by a 
permanent 2/0 silk tie and the ligated lobes were resected. In the 35 
per cent hepatectomy group only the left lateral lobe was resected. 
In the sham group the temporary ligation was removed to re- 
establish the circulation. The liver was then returned to the 
peritoneal cavity and the laparotomy wound closed in one layer. 
The rats were killed after 28 days by an overdose of ether. The 
liver was removed, immersed in phosphate-buffered saline (PBS), 
and tumour growth was determined by counting the number of 
metastases on the surface of the liver lobes. The livers were put on 
blotting paper for 30 s to remove excess PBS and were then 
weighed immediately. Experimental groups contained five to eight 
animals. 
Tumour necrosis factor a 
TNF-a was provided in lyophilized form by Knoll (Ludwigshafen, 
Germany). The product was 99 per cent pure, contained less than 
10 pg endotoxin per mg protein and had a specific activity of 
6.63 x loh units/mg. It was reconstituted in PBS before injection 
and was given intravenously in a dose of 160 pg/kg in 0.2 ml PBS, 
three times per week, starting on the day of operation. Control treat- 
ment consisted of 0.2 ml PBS according to the same schedule. On 
completion of sham operation or 70 per cent hepatectomy the rats 
were randomized and assigned to control or TNF-a treatment. 
Statistical analysis 
The number of tumour colonies on the surface of the liver lobes was 
counted. When more than 100 metastases were present, the number 
was scored as > 100. Results were analysed with the Mann- 
Whitney U test for comparison of non-parametric data and 
expressed as median (range). The mean liver weight was compared 
using Student’s unpaired t test. Significance was accepted at 
P < 0.05. 
Results 
Effect of partial hepatectomy on turnour growth 
The numbers of metastases 28 days after 35 or 70 per cent 
hepatectomy are shown in Table I .  A 35 per cent resection 
induced a significant increase in the number of metastases 
(P=O.O44) but not in wet liver weight. The number of 
tumours in the control group ranged from 0 to 20 (median 
3), and from 10-57 (median 28) in the 35 per cent 
hepatectomy group. A 70 per cent resection induced an even 
greater increase in tumour development. In all rats receiving 
this operation the number of tumours exceeded 100, 
whereas that in the controls ranged from 0 to 3 1 (median 7). 
Following 70 per cent hepatectomy there also was a 
significant increase in wet liver weight (P=0.006). The 
experiment involving 70 per cent resection was repeated four 
times, each time giving similar, significant, results. Fig. I 
shows the explosive tumour growth in a 70 per cent resected 
liver and can be compared with the appearance of a control 
liver in Fig. 2. In sham-operated rats no tumour was found in 
any of the lobes ligated during tumour cell injection. 
Antitumour effect of tumour necrosis factor a 
The results of treatment of sham-operated and 70 per cent 
hepatectomized rats with TNF-a are shown in Table 2. In the 
Fig. 1 Tumour growth following 70 per cent hepatectomy 
Fig. 2 Tumour growth following sham operation 
Table 2 Effect of tumour necrosis factor a on growth of liver 
metastases 28 days after 70 per cent hepatectomy or sham 
operation 
Table 1 Liver metastasis and wet liver weight 28 days after tumour 
cell injection 
Median (range) Mean(s.d.) 
no. of wet liver 
Incidence metastases weight (g) 
Median (range) Mean(s.d.) 
no. of wet liver 
0 per at i o n Incidence metastases weight (g) 
70 per cent hepatectomy 6 of 6 > 1001 2 2 q  8.9)$ 
Sham* 5 o f 6  7 (0-31) 10.6(0.9) 
28618-57# ko.yt.3) 
3 (0-20) 10.2(0.3) 
mw- 5 4 5  
Sham* 5 o f 6  
*Remaining lobes ligated during injection of tumour cells, but not 
removed. t P  < 0.05 versus sham (Mann-Whitney U test); $P < 0.05 
versus sham (Student’s t test) 
TNF-a treatment 
70 per cent hepatectomy 6 of 6 45 (5 ->  loo)? 12.4(6.4) 
Sham* 2 0 f 5  0 (0-7) 9.0(0.6) 
70 per cent hepatectomy 5 of 5 
Sham* 5 o f 8  3.5 (0- > 100) 8.7( 1.2) 
Control treatment 
> l00$ 22.3( 8.4)s 
TNF, tumour necrosis factor. *Remaining lobes ligated during 
injection of tumour cells, but not removed. tP < 0.05 versus sham 
and 70 per cent hepatectomy control treatment; $P < 0.05 versus 
sham (Mann-Whitney U test). §P<O.O5 versus sham (Student’s t 
test) 
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sham-operated group treatment with TNF-a had no 
significant effect on tumour growth compared with that in 
non-treated sham-operated controls (range 0-7 versus 
0- > 100 tumours respectively). Following 70 per cent 
resection, treatment with TNF-a was very effective and 
resulted m a qnifrant inhibkion oftamom growtfi- range 
5-> 100 (median 45) tumours in the treated group versus 
> 100 tumours in all non-treated animals. The decrease in 
tumour load following TNF-a treatment was confirmed by a 
significantly decreased mean( s.d.) liver weight ( 12.4(6.4) 
versus 22.3( 8.4) g respectively). Clinical signs of toxicity due 
to TNF-a treatment were not observed. 
Discussion 
The first finding in these experiments is that partial 
hepatectomy provokes increased tumour growth in the liver 
remnant. In repeated experiments an increase was found in 
wet liver weight and in the number of tumours after partial 
hepatectomy. To investigate whether the degree of growth 
promotion was proportional to the amount of liver resected, 
the effects of 70 and 35 per cent hepatectomy were 
compared, and it was found that this was indeed the case. 
Although both procedures significantly increased tumour 
growth, the effect of a 70 per cent resection was far greater. 
These findings confirm previous results obtained with 
various tumour models in  rat^^-^. Using the same CC531 
tumour model as described in the present study, K. P. de 
Jong et al. (personal communication) recently found that 
partial hepatectomy also enhances the growth of established 
liver metastases. It thus appears that, in this model, partial 
resection affects not only the outgrowth of fresh artificial 
metastases but also the proliferation of established tumours, 
thereby mirroring the clinical situation to an even greater 
degree. However, results of studies performed pre- 
dominantly in mice disagreed with these findings, and 
showed that partial resection did not lead to stimulation of 
tumour growth but rather to growth The 
inhibition of growth observed in the latter models has been 
ascribed to the immunostimulatory effects of partial 
resection, whereas immunosuppression and the release of 
growth factors have been held responsible for the enhanced 
tumour growth in rats. In the present rat model a likely 
explanation for the observed effect of partial resection is 
immunosuppression. A previous study2’ showed that tumour 
CC531, which is weakly immunogenic, exhibits enhanced 
growth when recipients are treated with the immuno- 
suppressive drug cyclosporin. In addition, Heuff et a1.22, 
using exactly the same model as the present authors2’, found 
that selective elimination of Kupffer cells resulted in strongly 
enhanced growth of liver metastases, similar to the explosive 
growth following partial resection in the present study. 
Although there is no direct evidence, it is tempting to 
speculate that partial resection leads to a depression of the 
natural cytotoxicity normally exhibited by Kupffer cells, 
resulting in accelerated tumour growth. 
There are various theories regarding the origin of new 
metastases in the liver that give rise to detectable recurrence. 
Tumour cells can spread from primary tumour cells in the 
liver remnant or from extrahepatic secondaries to form de 
novo metastases in the liver. Also, tumour cells that are 
spread during partial hepatectomy can settle again in the 
liver’. However, it is most likely that micrometastases not 
detected by preoperative or intraoperative screening grow to 
form detectable m e t a ~ t a s e s ~ ~ . ~ ~ .  It has been suggesteds that 
most of the occult metastases are single tumour cells that are 
spread throughout the liver. These dormant tumour cells 
could be triggered to start proliferating by changes in extra- 
cellular host factors. Liver regeneration after partial 
resection could provide such a trigger for metastatic growth. 
ft is conceivabk that, m this phase of turnour d-, 
adjuvant therapy would be particularly effective. 
Treatment with TNF-a was found to reduce the number of 
metastases in the liver remnant. The antitumour effect was 
more prominent in regenerating than in sham-operated liver, 
suggesting that the process of regeneration provides optimal 
conditions for TNF-a to be effective. However, tumour 
growth in the sham-operated livers was low, so firm 
conclusions on the relative inadequacy of TNF-a in non- 
hepatectomized livers cannot be drawn. 
Earlier studies on the efficacy of adjuvant therapy 
following partial resection in the rat provided evidence that 
5-fluorouracil (5-FU) and mitomycin C both were effective 
in reducing the enhanced tumour growth’. However, 
whereas the effect of mitomycin was found to be due to 
direct antitumour cytotoxicity, that of 5-FU was indirect and 
could be ascribed to inhibition of liver regeneration. In the 
present study the inhibition of tumour growth by TNF-a was 
not likely to be due to inhibition of liver regeneration. A pilot 
study has shown that treatment with TNF-a in doses ranging 
from 10 to 160 pg/kg on days 0 and 3 does not affect liver 
regeneration as assessed by wet liver weight on day 6 after 70 
per cent hepatectomy (unpublished results). In addition, 
repeated injection of TNF-a to hepatectomized and intact 
rats stimulates DNA synthesis in hepatocytes, resulting in an 
increased liver cell If confirmed, these latter 
findings imply that, depending on dose and timing of 
administration, TNF-a may show two opposing effects: 
inhibition of tumour growth on the one hand and a counter- 
productive stimulation of liver regeneration on the other. In 
the clinical situation this undesired effect might be counter- 
acted by combining TNF-a with chemotherapy. 
The clinical results obtained so far with systemic 
administration of TNF-a have not met the expectations 
raised by numerous animal studies2’. The few studies28,2’ 
performed with TNF-a in patients with colorectal cancer 
have provided no evidence of antitumour efficacy. However, 
interest in using TNF-a clinically has recently been rekindled 
by the remarkable efficacy of locoregional treatment with 
TNF-a (combined with interferony and chemotherapy) in 
patients with melanoma and ~ a r c o m a ~ ~ ~ ~ ~ .  In agreement with 
this new approach are the positive results obtained with 
locoregional treatment of liver metastases from patients with 
colorectal cancer. Van der Schelling et found stable 
disease after injection of TNF-a directly into liver 
metastases, whereas Mavligit and colleagues33 observed a 14 
per cent partial tumour response following TNF-a infusion 
via the hepatic artery. These studies indicate that TNF-a has 
definite antitumour activity in colorectal cancer metastatic to 
the liver. This observation, combined with the results 
obtained in the present study, supports the notion that a 
combination of metastasectomy and locoregional adjuvant 
therapy with TNF-a, preferably combined with chemo- 
therapy, may be of benefit in patients with liver metastases 
from colorectal cancer. 
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